- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03257462
Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
A Phase 2, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Efficacy of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia (CAH)
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a 6-week, multiple-dose, dose escalation study of SPR001 for the treatment of adults with classic CAH. After screening, eligible patients will be enrolled into a 6-week treatment period followed by a 4-week washout/safety follow-up period.
It is initially planned that up to approximately 18 patients in 2 dose cohorts will be enrolled. Additional patients or dose groups may be considered based upon specific safety, PK/PD, and/or efficacy findings, or if an active dose has not yet been reached.
SPR001 will be administered as an oral daily dose. Patients will undergo titration of SPR001 through three escalating dosage strengths at 2-week intervals. Patients will have overnight PK/PD assessments performed at baseline, which include an pre-dose overnight assessment and a post-dose overnight assessment for PK/PD following administration of the first dose. At the end of each 2-week dosing period, patients will return for single overnight visits for steady-state PK/PD assessments.
A follow-up outpatient visit will occur 30 days after their last dose.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Orange, California, United States, 92123
- Spruce Biosciences Clinical Site
-
San Diego, California, United States, 92123
- Spruce Biosciences Clinical Site
-
-
Florida
-
Melbourne, Florida, United States, 32935
- Spruce Biosciences Clinical Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30046
- Spruce Biosciences Clinical Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Spruce Biosciences Clinical Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Spruce Biosciences Clinical Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55414
- Spruce Biosciences Clinical Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89148
- Spruce Biosciences Clinical Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Spruce Biosciences Clinical Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients age 18 or older.
- Documented diagnosis of classic CAH due to 21-hydroxylase deficiency
- Elevated 17-OHP at screening
- On a stable glucocorticoid replacement regimen for a minimum of 30 days
Exclusion Criteria:
- Clinically significant unstable medical condition, illness, or chronic disease
- Clinically significant psychiatric disorder.
- Clinically significant abnormal laboratory finding or assessment
- History of bilateral adrenalectomy or hypopituitarism
- Pregnant or nursing females
- Use of any other investigational drug within 30 days
- Unable to understand and comply with the study procedures, understand the risks, and/or unwilling to provide written informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort A
The first cohort of 9 patients will be administered SPR001 at dose strength of Dose A daily for 2 weeks, and escalating through Dose B per day for 2 weeks and Dose C per day for 2 weeks.
|
SPR001 Capsules
|
EXPERIMENTAL: Cohort B
Cohort B will begin enrollment after Cohort A has been fully enrolled.
Starting dose selection and the stepwise dosing paradigm for Cohort B will be determined by an interim review of safety and PK/PD data from from Cohort A.
|
SPR001 Capsules
|
EXPERIMENTAL: Cohort C
Cohort C will begin enrollment after Cohort B has been fully enrolled.
Starting dose selection and the stepwise dosing paradigm for Cohort C will be determined by an interim review of safety and PK/PD data from from Cohort A and B.
|
SPR001 Capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of SPR001 in patients with CAH
Time Frame: 6 weeks
|
Incidence of treatment-emergent adverse events; changes from Baseline to End-of-study in clinical laboratory parameters, physical examination findings, vital signs, ECG parameters
|
6 weeks
|
Change in 17-hydroxyprogesterone
Time Frame: 6 weeks
|
Change in 17-hydroxyprogesterone from Baseline to End-of-study
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in pharmacodynamic (PD) markers
Time Frame: 6 weeks
|
Changes in ACTH and androgens from Baseline to End-of-study
|
6 weeks
|
Maximum plasma concentration (Cmax)
Time Frame: 6 weeks
|
To evaluate the pharmacokinetic (PK) parameter of maximum plasma concentration (Cmax) of SPR001 in patients with CAH
|
6 weeks
|
Area under the concentration-time curve (AUC)
Time Frame: 6 weeks
|
To evaluate the PK parameter of area under the concentration-time curve (AUC) of SPR001 in patients with CAH
|
6 weeks
|
PK/PD relationships
Time Frame: 6 weeks
|
To explore the potential relationships between pharmacokinetics and pharmacodynamics
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Michael Huang, MD, Spruce Biosciences
- Principal Investigator: Richard Auchus, MD, PhD, University of Michigan
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Endocrine System Diseases
- Gonadal Disorders
- Disorders of Sex Development
- Urogenital Abnormalities
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Metabolism, Inborn Errors
- Adrenal Gland Diseases
- Steroid Metabolism, Inborn Errors
- Hyperplasia
- Adrenal Hyperplasia, Congenital
- Adrenogenital Syndrome
- Adrenocortical Hyperfunction
Other Study ID Numbers
- SPR001-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Adrenal Hyperplasia
-
National Institutes of Health Clinical Center (CC)Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedAdrenal Insufficiency | Congenital Adrenal Hyperplasia (CAH) | Excess AndrogenUnited States
-
Neurocrine BiosciencesCompletedCAH - Congenital Adrenal HyperplasiaUnited States
-
Neurocrine BiosciencesCompletedCAH - Congenital Adrenal HyperplasiaUnited States
-
Spruce BiosciencesCompletedCongenital Adrenal Hyperplasia | CAH - Congenital Adrenal Hyperplasia | CAH - 21-Hydroxylase DeficiencyUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Adrenal Hyperplasia (CAH)France
-
Crinetics Pharmaceuticals Inc.RecruitingCongenital Adrenal Hyperplasia | Classic Congenital Adrenal HyperplasiaBrazil, India, United States, Argentina, Italy, United Kingdom
-
Eunice Kennedy Shriver National Institute of Child...Active, not recruitingCongenital Adrenal Hyperplasia (CAH)United States
-
Hospices Civils de LyonCompletedClassic Congenital Adrenal HyperplasiaFrance
-
Diurnal LimitedNational Institutes of Health (NIH)CompletedCongenital Adrenal Hyperplasia | Adrenal Insufficiency | Endocrine DiseaseUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Adrenal HyperplasiaFrance
Clinical Trials on SPR001
-
Spruce BiosciencesCompletedPolycystic Ovary SyndromeUnited States
-
Spruce BiosciencesActive, not recruitingCongenital Adrenal HyperplasiaUnited States, Australia, Brazil, Canada, Denmark, Estonia, Germany, Ireland, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
-
Spruce BiosciencesCompletedCongenital Adrenal Hyperplasia | CAH - Congenital Adrenal Hyperplasia | CAH - 21-Hydroxylase DeficiencyUnited States
-
Spruce BiosciencesRecruitingCongenital Adrenal Hyperplasia | 21-OHDUnited States
-
Spruce BiosciencesActive, not recruitingCongenital Adrenal HyperplasiaUnited States, Australia, Brazil, Estonia, Germany, Korea, Republic of, Latvia, Lithuania, Poland, Romania, Spain, Sweden, Turkey, Canada, Italy, United Kingdom